Swedish Orphan Biovitrum (SOBI) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic growth and portfolio evolution

• Strategic portfolio now represents 64% of total business, driven by 39% growth in Q3 and strong performance across all regions.

• Acquisition of Arthrosi, a next-generation URAT1 inhibitor for gout, is expected to be highly accretive with a long patent life, supporting growth into the 2030s.

• Six major product launches are planned, including Altuviiio, Gamifant (secondary HLH), C3G/IC-MPGN, NASP, Tryngolza, and MCS, with launches spanning 2024 to 2028.

• Altuviiio has achieved over 60% market share in early launch countries, with most new patients switching from competitors.

• Tryngolza launch preparation targets both rare and broader indications, leveraging strong clinical data and a dedicated internal team.

Pipeline and development highlights

• Gamifant showed strong signals in phase II-A for interferon gamma-driven sepsis, with significant unmet need and high mortality rates.

• Regulatory milestones expected for C3G/IC-MPGN and Gamifant in Japan and Europe, with key data publications and decisions anticipated in 2024.

• Zynlonta's LOTIS-5 trial data readout is expected in H1 2024, and the Arthrosi transaction is targeted to close in Q1.

• Capital Markets Day scheduled for February 18 to provide further strategic orientation and discuss economic outlook.

Financial and market outlook

• Beyfortus remains a stable and growing earnings stream, with strong physician and reimbursement support despite public debate on RSV prevention.

• Increasing royalty rates for Beyfortus through 2028 help offset competitive risks, supporting investment in new growth opportunities.

• Optimism for sustained growth is underpinned by a robust late-stage pipeline, multiple launches, and strategic acquisitions.